Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H52NO4P |
Molecular Weight | 461.6584 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
InChI
InChIKey=SZFPYBIJACMNJV-UHFFFAOYSA-N
InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19216841Curator's Comment: description was created based on several sources, including:
https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43408 | http://adisinsight.springer.com/drugs/800005360
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19216841
Curator's Comment: description was created based on several sources, including:
https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43408 | http://adisinsight.springer.com/drugs/800005360
Perifosine is an orally active alkyl-phosphocholine compound with potential antineoplastic activity. Perifosine is an Akt inhibitor, which targets the pleckstrin homology domain of Akt, thereby preventing its translocation to the plasma membrane. Perifosine exerts Akt-dependent and Akt-independent effects, and although many preclinical studies have documented Akt inhibition by perifosine, clinical validation of these findings is lacking. Perifosine is in phase II and III clinical trials for the treatment of neuroblastoma, glioblastoma multiforme and other solid tumors.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25740692 | https://www.ncbi.nlm.nih.gov/pubmed/28290002
Curator's Comment: Known to be CNS penetrant in a non-human primate model. Human data not available.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. | 2005 Mar 15 |
|
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. | 2011 Jan 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01002248
50 mg once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9155530
Growth inhibitoy activities of Perifosine against selected human cell lines appeared to be slightly more potent than activity of miltefosine. Thus, IC50s of Perifosine for melanoma cell lines M14 and SK-NEL-28 were 2.6 uM/ml and 19.9 uM/ml respectively; for CNS cell line SF-295 – 3.1 uM/ml; for prostate cell line PC-3 – 1.5 uM/ml; for Colon cell lines KM12, HT29, HCT-116 – 0.2 uM/ml, 4.0 uM/ml and 10.2 uM/ml respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2188
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/10/740
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
||
|
FDA ORPHAN DRUG |
310010
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
||
|
FDA ORPHAN DRUG |
290909
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
||
|
NCI_THESAURUS |
C2089
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7645
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
C1727
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL372764
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
PERIFOSINE
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
C105905
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
148177
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
m8550
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID3048946
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
67272
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
157716-52-4
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
639966
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
100000082773
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
DB06641
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
SUB09728MIG
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY | |||
|
2GWV496552
Created by
admin on Fri Dec 15 16:02:24 GMT 2023 , Edited by admin on Fri Dec 15 16:02:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY